Immunovant (IMVT) Net Cash Flow (2019 - 2026)

Immunovant (IMVT) has 8 years of Net Cash Flow data on file, last reported at -$91.4 million in Q1 2026.

• Quarterly Net Cash Flow fell 126.91% year-over-year to -$91.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $188.4 million (up 142.02% YoY) and the FY2026 annual result came in at $188.4 million, up 142.02% from the prior year.
• Net Cash Flow fell to -$91.4 million in Q1 2026, from $472.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $472.3 million in Q4 2025 to a low of -$114.5 million in Q2 2025.
• A 5-year average of $22.0 million and a median of -$58.3 million in 2024 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow plunged 211.43% — and 2023, when it soared 1650.83%.
• Tracing IMVT's Net Cash Flow over 5 years: stood at $24.1 million in 2022, then soared by 1650.83% to $422.6 million in 2023, then plunged by 123.21% to -$98.1 million in 2024, then jumped by 581.39% to $472.3 million in 2025, then slumped by 119.36% to -$91.4 million in 2026.
• The last three Net Cash Flow figures came in at -$91.4 million (Q1 2026), $472.3 million (Q4 2025), and -$77.9 million (Q3 2025), per Business Quant data.